A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(1 site)
China
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin Municipality Age range
18 Years – 75 Years
Last updated October 2024